Truist Securities Maintains Hold on Inari Medical, Lowers Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Inari Medical and lowered its price target from $55 to $46.
October 14, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Inari Medical and lowered its price target from $55 to $46, indicating a more cautious outlook.
The lowering of the price target from $55 to $46 by Truist Securities suggests a less optimistic view on Inari Medical's future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100